Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
11.70
-1.60 (-12.03%)
At close: Mar 9, 2026, 4:00 PM EDT
11.98
+0.28 (2.39%)
After-hours: Mar 9, 2026, 7:02 PM EDT
Trevi Therapeutics Employees
Trevi Therapeutics had 34 employees as of September 30, 2025. The number of employees increased by 7 or 25.93% compared to the same quarter last year.
Employees
34
Change
7
Growth
25.93%
Revenue / Employee
n/a
Profits / Employee
-$1,348,765
Market Cap
1.50B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 34 | 7 | 25.93% |
| Jun 30, 2025 | 33 | 7 | 26.92% |
| Mar 31, 2025 | 31 | 6 | 24.00% |
| Dec 31, 2024 | 26 | 1 | 4.00% |
| Sep 30, 2024 | 27 | 2 | 8.00% |
| Jun 30, 2024 | 26 | -4 | -13.33% |
| Mar 31, 2024 | 25 | 3 | 13.64% |
| Dec 31, 2023 | 25 | 0 | - |
| Sep 30, 2023 | 25 | 2 | 8.70% |
| Jun 30, 2023 | 30 | 7 | 30.43% |
| Mar 31, 2023 | 22 | -1 | -4.35% |
| Dec 31, 2022 | 25 | 1 | 4.17% |
| Sep 30, 2022 | 23 | -3 | -11.54% |
| Jun 30, 2022 | 23 | 0 | - |
| Mar 31, 2022 | 23 | 0 | - |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Sep 30, 2021 | 26 | 4 | 18.18% |
| Jun 30, 2021 | 23 | 4 | 21.05% |
| Mar 31, 2021 | 23 | 4 | 21.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Vir Biotechnology | 367 |
| Nurix Therapeutics | 317 |
| Harmony Biosciences Holdings | 293 |
| Biohaven | 256 |
| Capricor Therapeutics | 160 |
| Kodiak Sciences | 123 |
| Nanobiotix | 103 |
TRVI News
- 13 hours ago - Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough - GlobeNewsWire
- 7 days ago - Trevi Therapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 20 days ago - Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 6 weeks ago - Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) - PRNewsWire
- 2 months ago - Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - PRNewsWire
- 3 months ago - Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer - PRNewsWire
- 3 months ago - Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond - Seeking Alpha
- 4 months ago - Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript - Seeking Alpha